CO2023010010A2 - Composición farmacéutica que comprende un derivado de difenilpirazina - Google Patents

Composición farmacéutica que comprende un derivado de difenilpirazina

Info

Publication number
CO2023010010A2
CO2023010010A2 CONC2023/0010010A CO2023010010A CO2023010010A2 CO 2023010010 A2 CO2023010010 A2 CO 2023010010A2 CO 2023010010 A CO2023010010 A CO 2023010010A CO 2023010010 A2 CO2023010010 A2 CO 2023010010A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
diphenylpyrazine derivative
diphenylpyrazine
derivative
diphenylpyrazin
Prior art date
Application number
CONC2023/0010010A
Other languages
English (en)
Inventor
Wenyu Dong
Katie Amssoms
Proost Eddy De
Kok Paul Hartman
Rene Holm
Kristof Kimpe
Greet Meurs
Maxim Verstraeten
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CO2023010010A2 publication Critical patent/CO2023010010A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende calcio;{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}acetato, en particular a inyectables de acción prolongada que comprenden el mismo, el uso de la composición farmacéutica para el tratamiento o prevención de enfermedades específicas, y un proceso para producirlo.
CONC2023/0010010A 2021-01-29 2023-07-27 Composición farmacéutica que comprende un derivado de difenilpirazina CO2023010010A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021052208 2021-01-29
EP2021082830 2021-11-24
PCT/EP2022/052073 WO2022162158A1 (en) 2021-01-29 2022-01-28 Pharmaceutical composition comprising a diphenylpyrazine derivative

Publications (1)

Publication Number Publication Date
CO2023010010A2 true CO2023010010A2 (es) 2023-08-09

Family

ID=80445780

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0010010A CO2023010010A2 (es) 2021-01-29 2023-07-27 Composición farmacéutica que comprende un derivado de difenilpirazina

Country Status (12)

Country Link
US (2) US20240091223A1 (es)
EP (1) EP4284334A1 (es)
JP (1) JP2024508377A (es)
KR (1) KR20230137312A (es)
AU (1) AU2022214282A1 (es)
CA (1) CA3206133A1 (es)
CL (1) CL2023002216A1 (es)
CO (1) CO2023010010A2 (es)
IL (1) IL304525A (es)
MX (1) MX2023008923A (es)
TW (1) TW202239408A (es)
WO (1) WO2022162158A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2023238952A1 (ja) * 2022-06-10 2023-12-14 日本新薬株式会社 医薬組成物
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
DK2246336T3 (da) 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
US11964050B2 (en) 2017-07-24 2024-04-23 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
EP3718537A4 (en) 2017-11-27 2021-11-10 Osaka University SITE-SPECIFIC LIPOSOMAL FORMULATION
JP7032732B2 (ja) 2018-03-01 2022-03-09 国立大学法人 東京大学 プラテンシマイシンの製造方法
US20220323437A1 (en) * 2019-06-11 2022-10-13 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
TW202114998A (zh) * 2019-08-19 2021-04-16 日商日本新藥股份有限公司 鹽

Also Published As

Publication number Publication date
EP4284334A1 (en) 2023-12-06
KR20230137312A (ko) 2023-10-04
JP2024508377A (ja) 2024-02-27
AU2022214282A1 (en) 2023-08-10
IL304525A (en) 2023-09-01
WO2022162158A1 (en) 2022-08-04
TW202239408A (zh) 2022-10-16
CA3206133A1 (en) 2022-08-04
US20240091223A1 (en) 2024-03-21
CL2023002216A1 (es) 2024-03-01
MX2023008923A (es) 2023-08-10
US20240216366A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
CO2023010010A2 (es) Composición farmacéutica que comprende un derivado de difenilpirazina
PT1274698E (pt) Perciquinina, metodo para a sua producao e sua utilizacao como medicamento
PE20241760A1 (es) Compuestos antivirales que contienen nitrilo
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
CL2008002394A1 (es) Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos.
CY1108085T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
AR050717A1 (es) Composiciones farmaceuticas
TR201910177T4 (tr) Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
CO6561830A2 (es) Vacuna de péptido ch3 de ige
AR036813A1 (es) Composiciones farmaceuticas
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
PA8583501A1 (es) Derivados de pirrolidona como inhibidores de maob
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BR112023022755A2 (pt) Composto cíclico possuindo efeito inibidor seletivo para kras, mas não para hras e nras
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.